Geron’s 2025 Close: RYTELO Growth, a Cash Buffer, and a 2026 Revenue Forecast That Keeps the Lights On

Key numbers at a glance

The biotech world rarely follows a straight line, but Geron is handing observers a few familiar milestones to latch onto. For the quarter ended December 31, 2025, RYTELO (imetelstat) net product revenue came in at $48.0 million, with the full-year total at $183.6 million. The company ended 2025 with a liquidity cushion of roughly $401 million in cash, cash equivalents, restricted cash and marketable securities.

On the cost side, Geron reported $255 million in total operating expenses for 2025, which the company notes sits within its prior guidance. Management frames this as a balance between driving demand for RYTELO and exercising financial discipline to lower operating expenses year over year.

Sequential momentum appears modest but meaningful: RYTELO demand rose 9% in Q4 2025 versus Q3 2025, and the company closed 2025 with approximately 1,300 ordering accounts.

Looking ahead, Geron provided a 2026 revenue forecast for RYTELO in the $220–240 million range, with total operating expenses projected in a similar neighborhood of $230–240 million. In other words, the company aims to grow topline while maintaining tighter cost control as it scales adoption in its target markets.

What the numbers imply for the business

Commercial momentum in a niche but pivotal space

RYTELO’s trajectory hinges on adoption in second-line, lower-risk myelodysplastic syndromes (LR-MDS) and related settings. The company stresses that the drug’s FDA label, NCCN guidelines, and a growing body of evidence underpin its commercial case. The 9% QoQ lift in Q4 2025 signals growing interest, even as the base remains modest by biotech standards. The expanding ordering base (~1,300 accounts) suggests a widening net, though the real question is how many of those accounts translate into durable revenue streams and durable payer coverage.

Costs and discipline as a feature, not a bug

With 2025 expenses at $255 million and a 2026 operating expense guide of $230–240 million, Geron is signaling a shift toward more disciplined profitability metrics even as it pushes to grow revenue. In biotech terms, this is the delicate act: invest enough to broaden RYTELO's footprint while avoiding an outsized burn as a single-asset company. The market will likely parse whether the 2026 plan is robust enough to produce an earnings-per-share (EPS) trajectory that could trend toward earnings growth, even if quarterly EPS remains a point of curiosity for some time.

EPS, earnings surprise, and the roadmap to clarity

This release does not provide an EPS figure or a defined EPS consensus. Investors will watch the upcoming conference call for detail on quarterly EPS versus consensus estimates, and whether Geron can turn topline progress and cost discipline into a meaningful earnings surprise in a year where the math matters for a stock with higher headlines than cash burn. In the meantime, the absence of an explicit EPS datapoint means the market will lean on the narrative around revenue growth, cost management, and potential milestones to gauge the earnings trajectory.

Clinical and scientific momentum

Beyond the financials, Geron highlighted several publications expanding the evidence base for imetelstat. The company announced three new medical publications, including work in Blood Cancer Journal on the impact of prior therapy in LR-MDS, a Leukemia article on molecular disease markers in LR-MDS, and a Haematologica manuscript examining patient-reported outcomes in the Phase 3 IMerge trial. The announcements reinforce the market narrative that RYTELO has a broader evidence story beyond the approved label, which could influence physician adoption and payer positioning over time.

Geron also notes that it expanded the scientific body of evidence around RYTELO at the 2025 American Society of Hematology (ASH) Annual Meeting. Initial data from upcoming real-world experience trials and mechanistic studies are positioned for release in 2026, particularly in earlier-line settings and combination strategies. If these data points land with credibility, the company could see a more durable revenue path as the LR-MDS segment evolves.

Guidance and strategic posture for 2026

The company’s forward-looking numbers center on a 2026 RYTELO net product revenue target of $220–240 million and total operating expenses in a similar range of $230–240 million. This hints at a plan to sustain demand generation while avoiding a broadening cost base that might outpace revenue gains. Management described a strategic focus on U.S. commercial growth, international access pathways, and opportunistic innovation as it aims to transform Geron into a leading, sustainable hematology company.

Additionally, Geron signaled continuity in its RYTELO-focused strategy through 2026, including the IMpactMF interim analysis in relapsed/refractory myelofibrosis expected in the second half of 2026 and new real-world data efforts in LR-MDS. The net effect could be a more nuanced narrative for investors—one that blends drug adoption with evidence generation as a driver of long-run value rather than a quick-acceleration plotline.

From a market perspective, the combination of a defined revenue forecast, a disciplined expense outlook, and a visible uptick in RYTELO demand creates a plausible runway for the stock to be priced in line with a mid-size biotech that has a single primary asset and a clear path to scale—even if the EPS story remains in mid-building mode for now.

Liquidity position and year-end context

The liquidity snapshot—roughly $401 million in cash, cash equivalents, restricted cash and marketable securities at year-end 2025—gives Geron a degree of optionality as it pivots toward commercial activities and evidence generation. This buffer helps mitigate funding risk while the company invests to stimulate demand for RYTELO and absorbs ongoing clinical and publication efforts that underpin the broader LR-MDS narrative.

Conference call and next steps

Geron set a conference call and webcast for February 25, 2026, at 8:00 a.m. ET to discuss the fourth quarter and full-year 2025 results and strategic updates. For investors, the call will be the primary venue to gather details on EPS expectations, the cadence of new data releases, and any revisions to the 2026 revenue and expense outlook. Absent a surprise in the numbers, the call will likely emphasize execution, payer dynamics, and the continued push to broaden RYTELO’s footprint in LR-MDS and related indications.

Takeaways for the sector and peers

Geron’s year-end narrative underscores a few persistent themes in small-cap biopharma: (1) a single-asset company with a clear regulatory narrative can still produce meaningful topline progress if it aligns with a growing disease area and a credible clinical evidence story; (2) a liquidity cushion matters when the business model blends commercialization with ongoing development and publications; and (3) market participants will weigh 2026 guidance not just against this year’s numbers, but against the implied path to earnings clarity as the company navigates a cost structure that still relies on early-stage commercialization heft.

For peers in LR-MDS and hematology, Geron’s stance—targeted, evidence-backed growth paired with cost discipline—offers a blueprint for balancing commercial investments with a credible long-range plan. If the 2026 data cadence lands with credibility, several rivals could pivot from wait-and-see to more assertive market access strategies, particularly where payer ecosystems and NCCN-style endorsements begin to converge with real-world outcomes data.